You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康恩貝(600572.SH):金華康恩貝的EVT-401片藥物臨牀試驗獲批
格隆匯 08-24 18:17

格隆匯8月24日丨康恩貝(600572.SH)公佈,近日,浙江康恩貝製藥股份有限公司控股子公司浙江金華康恩貝生物製藥有限公司(簡稱:金華康恩貝)收到國家藥品監督管理局核准簽發的EVT-401片藥物臨牀試驗批准通知書。

此次臨牀試驗申請EVT-401片的適應症為類風濕性關節炎。藥理作用為EVT-401的作用靶點是P2X7;P2X7受體是一種非選擇性陽離子通道,該通道可被ATP或ATP類似物和抗微生物肽LL-37調控,P2X7受體主要在免疫系統的細胞表達,如單核細胞和巨噬細胞,通過調節細胞因子(如IL-1β)從而在炎症過程中發揮重要的作用。

截至目前,金華康恩貝對EVT-401片投入的研發費用約2280萬元人民幣。經查詢,國內暫無同類產品獲批上市。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account